Please assess the completion status of the following clinical trial:

Trial Title: BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histological or cytological proof of pancreatic adenocarcinoma; must have locally advanced or metastatic pancreatic cancer who have received at least first line chemotherapy and may have responding, stable or progressive disease~* Expected survival \>= 3 months~* Karnofsky performance scale (KPS) \>= 70% or Southwestern Oncology Group (SWOG) performance status 0 or 1~* Absolute neutrophil count (ANC) \>= 1,000/mm\^3~* Lymphocyte count \>= 400/mm\^3~* Platelet count \>= 75,000/mm\^3~* Hemoglobin \>= 8 g/dL~* Serum creatinine \< 2.0 mg/dl, creatinine clearance \>= 50 ml/mm (can be calculated or measured)~* Total bilirubin =\< 2 mg/dl (biliary stent is allowed)~* Serum glutamate pyruvate transaminase (SGPT) and serum glutamic oxaloacetic transaminase (SGOT) \< 5.0 times normal~* Left ventricular ejection fraction (LVEF) \>= 45% at rest (multigated acquisition scan \[MUGA\] or echocardiogram \[Echo\])~* Females of childbearing potential, and males, must be willing to use an effective method of contraception~* Females of childbearing potential must have a negative pregnancy test within 7 days of being registered for protocol therapy~Exclusion Criteria:~* Any chemotherapy related toxicities from prior treatment (\> grade 2 per Common Terminology Criteria for Adverse Events \[CTCAE\] version \[v\]4.0)~* Known hypersensitivity to cetuximab or other EGFR antibody~* Treatment with any investigational agent within 14 days prior to being registered for protocol therapy~* Symptomatic brain metastasis~* Chronic treatment with systemic steroids or another immuno-suppressive agent~* Serious non-healing wound, ulcer, bone fracture, major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to being registered for protocol therapy~* Active liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis~* Known human immunodeficiency virus (HIV) infection~* Active bleeding or a pathological condition that is associated with a high risk of bleeding (therapeutic anticoagulation is allowed)~* Has an active infection requiring systemic therapy~* A serious uncontrolled medical disorder that in the opinion of the investigator may be jeopardized by the treatment with protocol therapy~* Females must not be breastfeeding~* Patient (Pt) may be excluded if, in the opinion of the principal investigator (PI) and investigator team, the pt is not capable of being compliant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (anti-CD3 x anti-EGFR BATs) (Type: EXPERIMENTAL): Patients receive one of the following standard chemotherapy regimens at the discretion of the treating physician: gemcitabine hydrochloride IV over 30 minutes; gemcitabine hydrochloride IV over 30 minutes and paclitaxel albumin-stabilized nanoparticle formulation IV over 30-40 minutes; oxaliplatin IV over 2 hours, fluorouracil IV over 46 hours and leucovorin calcium IV over 2 hours; or fluorouracil IV over 46 hours, leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV, and oxaliplatin IV over 2 hours. Approximately 2 weeks after standard chemotherapy completion, patients receive anti-CD3 x anti-EGFR-bispecific antibody armed activated T-cells IV over 5-30 minutes twice weekly for 4 weeks. Patients also receive aldesleukin SC and sargramostim SC on day -3 before the first anti-CD3 x anti-EGFR-bispecific antibody armed activated T-cells infusion and continuing twice weekly until the final infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).